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Abstract
Objective: Data about vitamin B12 (B12) deficiency in the general population are
scarce. The present study was performed to determine the prevalence of B12
deficiency in the general population of the Principality of Liechtenstein, as well as
to identify sub-populations potentially at high risk.
Design: Retrospective study.
Setting: Ambulatory setting, population of the Principality of Liechtenstein.
Subjects: Seven thousand four hundred and twenty-four patients seeking medical
attention whose serum samples were referred for routine work-up in an ambu-
latory setting were consecutively enrolled. Serum total B12 was determined in all
patients in this cohort. In addition, for a subgroup of 1328 patients, serum
holotranscobalamin was also measured. Prevalence of B12 deficiency was
calculated. Further, multivariate logistical regression models were applied to
identify covariates independently associated with B12 deficiency and depletion.
Results: Nearly 8% of the general population was suffering from either B12
depletion or deficiency. The ratio between B12 depletion and deficiency was 2:1
for all age ranges. Pathological changes were detected predominantly in older
people. Female gender was a significant predictor of B12 depletion. In the cohort,
nearly 40% exhibited either depletion or deficiency of B12.
Conclusions: B12 depletion and deficiency are common in Liechtenstein, a Central
European country. The measurement of biochemical markers represents a cost-
efficient and valid assessment of the B12 state. When a deficiency of B12 is
diagnosed at an early stage, many cases can be treated or prevented, with
beneficial effects on individual outcomes and subsequent potential reductions in
health-care costs.
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Vitamin B12 (B12, cobalamin) is a water-soluble vitamin
and an essential nutrient that normally must be obtained
from the diet. Metabolically, it is essential for two reac-
tions catalysed by the enzymes methionine synthase and
L-methyl-malonyl-coenzyme A mutase. The daily recom-
mended daily intake of B12 for adults is 2mg
(1). In healthy
individuals, nutritional B12 deficiency is unusual because
total body stores in adults are about 2500mg and daily
turnover is slow(2), meaning that reserves generally remain
for up to 10 years(3). B12 deficiency can have many causes,
such as nutritional habits (strict vegetarian and vegan
diets: practice of abstaining from use of animal products),
intestinal malabsorption (i.e. gastritis, state after total
gastrectomy), use of proton pump inhibitors and elevated
requirements (hyperthyroidism)(2).
Severe and persistent B12 deficiency has relevant
adverse effects on clinical condition, namely haematolo-
gical, neurological, neuropsychiatric and metabolic
dysfunctions (i.e. methyl-malonyl-coenzyme A acidosis,
hyperhomocysteinaemia)(3–5). Mild B12 deficiency nor-
mally does not provoke clinical symptoms, but can be
diagnosed by measurement of blood markers. The clin-
ical laboratory parameters available to diagnose B12
deficiency are serum total B12, transcobalamin-bound B12
(holotranscobalamin, HoloTC: active fraction of B12),
plasma homocysteine (Hcy) and methylmalonic acid
(MMA)(6). The metabolites Hcy and MMA can be used as
indicators of B12 deficiency, but many factors other thany Contributed equally to this manuscript.
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B12 deficiency (e.g. renal failure) can increase Hcy and
MMA. Furthermore, measuring MMA is complicated and
expensive, requiring HPLC or GC–MS(7). Thus algorithms
for laboratory diagnosis of a B12-deficient status recom-
mend the initial measurement of B12 and HoloTC. Clarke
et al. state that HoloTC has better diagnostic accuracy
than B12 (77% v. 73%) and that the diagnostic utility is
superior in the overall population as well as in patients
with renal impairment(8).
B12 deficiency is characterized by low serum concentra-
tions of total B12 (,148pmol/l) and HoloTC (,35pg/l),
whereas depletion shows total B12 within the grey zone
(148–221pmol/l) and HoloTC lower than the cut-off(4,8,9).
To date, an internationally valid consensus as to the defi-
nition of B12 deficiency has not been established, since
different thresholds have been used(9). The transition from
B12 depletion to deficiency is fluid. The early diagnosis of a
deficient status is essential because simple B12 supple-
mentation may reverse clinical symptoms.
B12 deficiency is prevalent primarily in elderly people,
children and women of reproductive age, with pre-
valences ranging from 10 to 40%(4,8,10–13). In general, no
relationship between B12 status and geographic distribu-
tion of the population can be claimed(10). The condition
has the potential to be a worldwide public health problem.
The aim of the present study was to investigate the pre-
valence of B12 depletion and deficiency based on serum
total B12 and HoloTC concentrations in a representative
population of Liechtenstein. Our secondary aim was to
determine factors associated with depletion and deficiency.
Materials and methods
Study population
The current retrospective study was carried out in the
resident population of the Principality of Liechtenstein,
without age restrictions. The study period ranged from
January 2000 until December 2007. Within the study
period, the population of Liechtenstein averaged 35 168
permanent residents of nearly exclusively Caucasian ori-
gin, as described elsewhere(14). Corrected for migration
and deaths, the reference population totals 38 839.
Serum samples of 7424 consecutive patients from child
age to advanced age seeking medical attention by their
physicians, referred for routine laboratory work-up in an
ambulatory setting, were included in the study. Out of
them, a subgroup of 1328 patients was also evaluated.
Hospitalized patients were excluded from the study.
In the case of multiple determinations in the same indi-
vidual, only the lowest value was kept in the database
and used for further analysis.
Laboratory methods
Venous blood samples were drawn from all individuals in
fasting or non-fasting state into Vacutainer tubes (BD
Systems, Basel, Switzerland) or Sarstedt Monovette tubes
(Sarstedt, Sevelen, Switzerland). The samples were
referred to the Liechtenstein central laboratory. Serum
total B12 was measured within 24 h after venepuncture.
For measurement of total B12 concentrations, a competi-
tive-binding immunoenzymatic assay employing chemi-
luminescence was used (Access Vitamin B12, run on two
different analysers, Access2 and Unicel DxI800 instruments
(Beckman Coulter, Nyon, Switzerland), whose agreement
was previously compared).
In a subgroup of 1328 patients investigated during
2007, also HoloTC levels were measured on the Abbott
AxSYMR immunochemical automated analyser (Abbott
Diagnostics, Baar, Switzerland). The between-day CV, as
evaluated by commercially available control materials,
were 4?5% (at 242 pmol/l), 5?5% (at 360 pmol/l) and
6?3% (at 911 pmol/l) for total B12 and 8?7% (at 21 pmol/l)
and 9?7% (at 52 pmol/l) for HoloTC.
According to the country’s validated laboratory refer-
ence values, the cut-off point for B12 deficiency was
defined as serum level of total B12 ,125 pmol/l
(15). The
cut-off point for B12 depletion was defined as a serum
level of 125–300 pmol/l for total B12 and a serum level of
,35 pg/l for HoloTC(9).
Statistical analysis
The proportion of individuals with a B12 measurement
among the general population was assessed across different
age strata by using the national census data controlled for
cases of migration and deaths. The prevalence of individuals
with B12 depletion or deficiency was calculated within
the cohort. Further, the prevalence of these individuals
among the general population was determined by using
the adjusted national census data. Differences between
proportions were assessed with the x2 test. Finally, a logistic
regression model was applied in order to detect associations
between demographic factors such as age and gender and
the presence of B12 deficiency. A P value less than 0?05 was
considered statistically significant.
Results
A total of 7424 patients who sought medical attention
were included in the study (ambulatory setting). This
cohort comprised 19?1% of the country’s entire popula-
tion. The baseline characteristics of the study cohort are
given in Table 1. Mean serum total B12 levels fluctuated
from 199 to 226 pmol/l between the different years.
Remarkably, only 12?4% of the cohort had a serum
total B12 level in a reference interval where B12 deficiency
is unlikely (.300pmol/l); 74?2% of the cohort were within
the grey zone (125–300pmol/l), exhibiting B12 depletion,
while 13?4% of the cohort showed evidence of B12 defi-
ciency (,125pmol/l). In the subgroup of participants
with simultaneous total B12 and HoloTC determination,
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B12 depletion was seen in 26?4% (i.e. B12 grey zone together
with HoloTC,35pmol/l). The mean total B12 levels and the
mean HoloTC levels across the different age/gender strata
are shown in Fig. 1.
The ratio between the prevalence of B12 deficiency and
depletion was investigated in both the general population
and the study cohort (Table 2). Population prevalence of
B12 deficiency was obtained by calculating the ratio of
individuals with B12 deficiency among the reference
population of 38 839. Population prevalence of B12 deple-
tion was extrapolated from the ratio between individuals
with B12 depletion and B12 deficiency in the study cohort
(2:1). Taking these findings into account allowed estimation
of the prevalence of B12 depletion and deficiency among
the general population at nearly 8% (Table 2).
Stratifying the cohort with regard to gender and age
showed that the prevalence of B12 deficiency was sig-
nificantly higher in females than in males (14?85% v.
10?51%, respectively, P, 0?001) and in persons aged
50 years and older than in those younger than 50 years
(15?47% v. 11?79%, respectively, P, 0?001; Fig. 2).
Interestingly, there was a bimodal distribution of the
prevalence within females, with a first peak at childbearing
age. The subgroup having both total B12 and HoloTC
measurements paralleled these findings, but demonstrated
higher prevalence among all age groups (Fig. 3). Surpris-
ingly, a remarkable B12-deficient status was already seen
in children.
Further calculating the prevalence of B12 deficiency
within the general population revealed characteristics
Table 1 Baseline characteristics of the study populations; ambulatory setting, Principality of Liechtenstein, January
2000–December 2007
Total cohort Subgroup with HoloTC measurement
Variable n % n %
No. of participants 7424 100 1328 100
Gender
Female 4915 66?2 884 66?6
Male 2512 33?8 444 33?4
Mean SD Range Mean SD Range
Age (years) 48 19 1–101 49 18 6–99
Mean serum total B12 (pmol/l) 230 130 11–1254 208 112 25–1144
Mean serum HoloTC (pmol/l) Not measured – – 45 31 3–624
HoloTC, holotranscobalamin; B12, vitamin B12.
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Fig. 1 Serum levels of (a) total vitamin B12 (B12) in the
study cohort (n 7424) and (b) holotranscobalamin (HoloTC) in
a subgroup of the cohort (n 1328), stratified according to
age and gender (’, male; &, female); ambulatory setting,
Principality of Liechtenstein, January 2000–December 2007.
Values are means with their standard errors represented by
vertical bars
Table 2 Prevalence of B12 depletion and deficiency in the cohort
and the general population of Liechtenstein
Cohort Population
B12 depletion
% 26?4 5?1
n/ncohort 524/1328
B12 deficiency
% 13?4 2?6
n/ncohort or npopulation 994/7424 994/38 839
B12, vitamin B12; HoloTC, holotranscobalamin.
Serum total B12 was determined in all individuals of the cohort (n 7424). B12
depletion was measured by total B12 and HoloTC assays; the cohort
with concomitant HoloTC determination comprised 1328 individuals. The
prevalence of B12 depletion in the general population was extrapolated from
the ratio between individuals with B12 depletion and B12 deficiency in
the cohort (2:1).
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similar to those within the cohort: older persons and
females suffer more often from B12 deficiency (Fig. 4).
Finally, a logistic regression model with age, gender
and the interaction between age and gender as predictors
of B12 deficiency found that age (OR5 1?32; 95% CI 1?23,
1?43) and female gender (OR5 5?81; 95% CI 3?41, 9?89)
were significant predictors of the presence of B12-deficient
status. Interestingly, the interaction between female gender
and age was also significant (OR50?80; 95% CI 0?73, 0?87),
indicating that the influence of age on the frequency of B12
deficiency is stronger in women than in men.
Discussion
In the present retrospective study we found that nearly 20%
of the population had a clinical suspicion of B12 deficiency.
About 40% of the cohort had biochemical evidence of
impaired B12 serum levels (26?4% depleted and 13?4%
deficient). Within the general population of Liechtenstein,
B12 deficiency is encountered in 2?6%, whereas the pre-
valence of B12 depletion can be estimated at 5?1%.
Comparing our data with other studies such as the
Framingham Study(11), which described 12% of elderly
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Fig. 3 Prevalence of vitamin B12 (B12) depletion (measured by total B12 and holotranscobalamin assays) in a subgroup of the
cohort (n 1328), stratified according to age and gender (’, male; &, female); ambulatory setting, Principality of Liechtenstein,
January 2000–December 2007
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Fig. 2 Prevalence of vitamin B12 (B12) deficiency in the study cohort (n 7424), stratified according to age and gender (’, male;
&, female); ambulatory setting, Principality of Liechtenstein, January 2000–December 2007
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people as suffering from B12 deficiency, we have to keep
in mind that we were able to consecutively determine B12
status in persons with clinical suspicion of B12 deficiency
within one entire country. Other studies have examined
B12 status in individuals randomly selected from the
population(10,16,17). Allen showed in a US sub-population
of individuals aged $60 years that the prevalence of B12
deficiency was 6% and the prevalence of B12 depletion
(marginal B12 status, HoloTC not assessed) was about
20%(4). According to Clarke et al., in approximately
5–20% of elderly people a B12 deficiency remains
undiagnosed(8). The prevalence of subclinical functional
B12 deficiency in the general population is higher than
expected(7).
There are hardly any population-wide studies about
B12 depletion or deficiency. The sub-populations exam-
ined mainly are elderly people (as mentioned above),
children and women of reproductive age. Children are of
special interest as early B12 deficiency leads to impaired
brain development and a higher risk of depression as an
adult(18). Our study shows that B12-deficient status occurs
at all ages, showing one peak in the third decade and
another in advanced age (from age 70 years onwards).
On the one hand, the capacity to absorb B12 from food
decreases in older people (i.e. atrophic gastritis, intestinal
dysfunction), consequently leading to a malabsorption
syndrome(19,20). On the other hand, the principal reason
for B12 malabsorption is the pharmacological decrease in
acid secretion in the stomach, causing an impairment of
protein-bound B12 absorption
(2). Drugs that decrease acid
secretion comprise 3?9% of all administered drugs in
Liechtenstein (Mag. Stefan Tomaselli, Liechtenstein Office
of Public Health, personal communication). However, in
our database, a link between antacid use and serum total
B12 concentration in an individual cannot be drawn.
Accordingly, we cannot provide evidence on the epide-
miological importance of antacid use as a cause of B12
deficiency.
Among young people in Madrid, Gil et al. appraised
4?8% as being deficient, with males more likely to be defi-
cient than females, whereas our data show a significantly
higher prevalence among girls within a similar percentage of
affected persons(21). This fact could be explained by the fact
that in Central European countries girls show a higher rate of
unhealthy dietary habits than boys(22–25).
Refsum et al. showed that total B12 and HoloTC con-
centrations were lower in women than in man, and they
increased with age(12). Further analyses in that study
revealed the age effect to be limited to women, and the
gender differences were confined to those aged #45
years. In women #45 years of age, there was a complete
shift of the HoloTC distribution towards lower con-
centrations of , 20%(12). Would that suggest gender as a
significant predictor for B12 deficiency? In our study about
5% of the females of this age showed a B12-deficient
status. B12 deficiency among females of reproductive age
has an important impact, as it can cause infertility and
abortion. Additionally, the fetus may suffer neural tube
defects and prematurity(26).
Data about B12 deficiency and/or depletion in men are
scarce. We could not identify a single study concentrating
on male individuals. In general they are mentioned among
either the elderly or subgroups (i.e. alcoholics, post-
gastrectomy state). In our trial men less often demonstrated
a deficient B12 status, but in association with age they had a
more pronounced risk of being affected (OR50?8). In our
cohort, males over the age of 80 years suffered even more
often from B12 impairment than women.
HoloTC is known to be a more sensitive and specific
marker than total B12, especially for subclinical functional
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Fig. 4 Prevalence of vitamin B12 (B12) deficiency in the general population of Liechtenstein, stratified according to age and gender
(’, male; &, female)
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B12 deficiency and depletion
(27). In this context it should
be kept in mind that, remarkably, B12 depletion occurs
twice as often as B12 deficiency. To our knowledge there
are no published studies discussing this issue. The pro-
blem in comparing different studies is that there are no
internationally agreed-upon reference laboratory values
for the stratification of B12 deficiency and there is no
widely accepted agreement about the therapeutic impli-
cations of B12 depletion. Patients showing manifest B12
deficiency have to be treated immediately after diagnosis,
as some clinical symptoms can be reversed(5).
The main limitation of our study concerns the lack of
performance of additional laboratory tests such as Hcy or
MMA. Both are comparably expensive and laboratory-
intensive tests. On the other hand, MMA concentration is
considered to be the most specific and sensitive para-
meter for diagnosis of B12 deficiency
(27). Furthermore, we
did not randomly analyse the population of Liechtenstein,
either with regard to subgroups like pregnant women or
individuals affected by metabolic disease. In addition, we
did not assess the health status and the illness for which
medical attention was sought.
Conclusions
B12 deficiency is a frequent finding in a Central European
population (2?6%), and B12 depletion is found twice
as often. Female gender and age are independent, sig-
nificant predictive factors of a B12-deficient state, and
regular monitoring of B12 status is recommended for
them. Current considerations for public health interven-
tions to prevent B12-associated pathologies in vulnerable
sub-populations are still under debate(28).
The measurement of total B12 and HoloTC concentra-
tions are two valid and easily performed parameters for
the detection of B12 deficiency. Early recognition of
subclinical depletion of B12 is essential, and treatment of
the deficiency is imperative, as symptoms can be reversed
at an early phase and may also be preventable. Diagnosis
of B12 status is important, uncomplicated, and can lead to
simple treatment, preventing major disabilities.
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